Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 09, 2022

Short vs Extended Treatment With a Carbapenem in Patients With High-Risk Fever of Unknown Origin During Neutropenia

The Lancet Haematology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial
Lancet Haematol 2022 Jun 09;[EPub Ahead of Print], NA de Jonge, JJ Sikkens, S Zweegman, A Beeker, P Ypma, AH Herbers, W Vasmel, A de Kreuk, JLLM Coenen, B Lissenberg-Witte, MHH Kramer, MA van Agtmael, JJWM Janssen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading